HERE IS A cover-length editorial on the virtues of GLP-1 receptor agonists, such as Ozempic and Wegovy. Dedicated readers will recognise it from our edition of October 26th 2024. We would like you to design an alternative cover to ours, with your own headline, and to send it as a pdf…